Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities Health Care Conference on Wednesday, May 15, 2024 at 4:20 p.m. Pacific Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-lead.

Masimo to Present in BofA Securities Health Care Conference

Masimo Corporation (NASDAQ:MASI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Eli Kammerman - Vice President of Business Development & Investor Relations Joe Kiani - Chairman & Chief Executive Officer Micah Young - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Wise - Stifel Marie Thibault - BTIG Vik Chopra - Wells Fargo Mike Polark - Wolfe Research Operator Good afternoon ladies and gentlemen and welcome to Masimo's First Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com.

Masimo Corporation (MASI) Q1 2024 Earnings Call Transcript

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Masimo (MASI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 50,400. Consolidated GAAP operating income was $34.0 million. Consolida.

Masimo Reports First Quarter 2024 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--The Masimo Stork™ baby monitoring system has received FDA clearance for use over the counter (OTC) without the need for a prescription.

Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System

Masimo has allowed founder Joe Kiani to pledge more than half his $660 million stake in the company as collateral for personal loans.

Masimo's billionaire CEO put shares on margin to get cash while keeping ownership ahead of proxy fight

DexCom

Intuitive Surgical

The value of the “global medical device market” is expected to jump from over $500 billion last year to nearly $800 billion “by 2030.” According to the World Health Organization, “a medical device can be any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article.

Medtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the.

Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7

Masimo's (MASI) R&D activities raise optimism about the stock.

Reasons Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?

SANTIAGO, Chile--(BUSINESS WIRE)--Masimo CEO Joe Kiani will speak at the Global Ministerial Summit on Patient Safety in Chile about how AI-based solutions can improve patient safety.

Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile

On March 22, 2024, Masimo MASI Corporation, a global leader in non-invasive monitoring technologies and audio products, announced that its Board of directors had authorized management to evaluate a proposed separation of its Consumer Business.

Masimo To Explore Spin-Off Of Its Consumer Unit

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today confirmed that Politan Capital Management LP (“Politan”) has provided notice of its intent to nominate two candidates to stand for election to the Masimo Board of Directors at the company's 2024 Annual Meeting. While Masimo respects and values the input and ideas of all its stockholders and respects their right to nominate and elect the directors of their choice, the Company believes that Politan's efforts to take control of the Board.

Masimo Responds to Politan Capital's Nomination of Director Candidates and Refutes Politan's False Claims

Here is how Masimo (MASI) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?

The medical-device maker has been approached by a potential joint venture partner, CEO Joe Kiani said.

Masimo May Look at Joint Venture for Consumer Split, CEO Says

Masimo stock broke out to an eight-month high Monday after the company said it could potentially separate its consumer-facing business.

Masimo Breaks Out To Eight-Month High On Proposed Consumer Biz Separation

Quentin Koffey's Politan Capital waged a successful proxy fight at Masimo last year, and it is now seeking two more board seats.

Activist investor plans second fight at Masimo, sending shares up 12%

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated: “.

Politan Nominates Two Independent Candidates for Masimo Board

Masimo Corp.'s stock MASI, +1.40% was up 12% in premarket trading on Monday after The Wall Street Journal reported that activist investor Politan Capital Management plans to nominate two more members to the patient-monitoring technology company's board. Politan Capital, which was launched by Quentin Koffey, already has two seats on the company's board.

Masimo's stock rallies on report of looming activist campaign, disclosure of spinoff plan

Share in Masimo (MASI) surged 13% in extended trading on Friday after the company announced that it is planning a spinoff of its consumer unit to improve the profitability of its primary healthcare business.

Masimo Stock Surges After Proposed Spinoff of Consumer Business

Politan Capital Management, founded by veteran activist Quentin Koffey, plans to nominate two director candidates to the company's six-person board.

Activist Politan Plans Second Proxy Battle at Masimo

Activist investor Politan Capital Management, which last year won two seats on the board of medical technology company Masimo Corp , is planning a second proxy battle for two more seats, the Wall Street Journal reported on Sunday.

Activist investor Politan plans second proxy battle at Masimo, WSJ reports

The Irvine, Calif.-based medical technology company expects the separation to include its consumer audio and consumer health products.

News for Masimo Stock (MASI)